{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:18:44Z","timestamp":1758709124420},"reference-count":56,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Combination therapy can successfully suppress human immunodeficiency virus (HIV) replication in patients but selects for drug resistance, requiring subsequent resistance-guided therapeutic changes. This report describes the development and validation of a novel assay that offers a uniform method to measure susceptibility to all clinically approved HIV type 1 (HIV-1) drugs targeting reverse transcriptase (RT), protease (PR), integrase (IN), and viral entry. It is an assay in which the antiviral effect on infection within a single replication cycle is measured in triply transfected U87.CD4.CXCR4.CCR5 cells, based on homologous recombination between patient-derived amplicons and molecular proviral clones tagged with the enhanced green fluorescent protein (EGFP) reporter gene and from which certain viral genomic regions are removed. The deletions stretch from p17 codon 7 to PR codon 98 in pNL4.3-\u0394gagPR-EGFP, from PR codons 1 to 99 in pNL4.3-\u0394PR-EGFP, from RT codons 1 to 560 in pNL4.3-\u0394RT-EGFP, from IN codons 1 to 288 in pNL4.3-\u0394IN-EGFP, and from gp120 codon 34 to gp41 codon 237 in pNL4.3-\u0394env-EGFP. The optimized experimental conditions enable the investigation of patient samples regardless of viral subtype or coreceptor use. The extraction and amplification success rate for a set of clinical samples belonging to a broad range of HIV-1 group M genetic forms (A-J, CRF01-03, CRF05, and CRF12-13) and displaying a viral load range of 200 to &gt;500,000 RNA copies\/ml was 97%. The drug susceptibility measurements, based on discrimination between infected and noninfected cells on a single-cell level by flow cytometry, were reproducible, with coefficients of variation for resistance ranging from 7% to 31%, and were consistent with scientific literature in terms of magnitude and specificity.<\/jats:p>","DOI":"10.1128\/jcm.01739-08","type":"journal-article","created":{"date-parts":[[2009,4,30]],"date-time":"2009-04-30T01:11:52Z","timestamp":1241053912000},"page":"2232-2242","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs"],"prefix":"10.1128","volume":"47","author":[{"given":"Kris","family":"Covens","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"}]},{"given":"Nathalie","family":"Dekeersmaeker","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"}]},{"given":"Yoeri","family":"Schrooten","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"},{"name":"AIDS Reference Laboratory, University Hospitals Leuven, Leuven, Belgium"}]},{"given":"Jan","family":"Weber","sequence":"additional","affiliation":[{"name":"Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Dominique","family":"Schols","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"}]},{"given":"Miguel E.","family":"Quin\u0303ones-Mateu","sequence":"additional","affiliation":[{"name":"Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio"}]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"}]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium"},{"name":"AIDS Reference Laboratory, University Hospitals Leuven, Leuven, Belgium"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000188422.95162.b7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/135965350601100512","volume":"11","year":"2006","unstructured":"Abecasis, A. B., K. Deforche, L. T. Bacheler, P. McKenna, A. P. Carvalho, P. Gomes, A. M. Vandamme, and R. J. Camacho. 2006. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther.11:581-589.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","volume":"17","year":"2003","unstructured":"Brenner, B., D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS17:F1-F5.","journal-title":"AIDS"},{"key":"e_1_3_2_5_2","unstructured":"Interpretation of drug susceptibility and replication capacity results from subtype C HIV-1 protease\/RT is not influenced by the subtype of the resistance test vector 2007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.010249"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btl508"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2006.09.004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0173"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bti607"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.18.8358-8367.2000"},{"key":"e_1_3_2_12_2","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2008"},{"key":"e_1_3_2_13_2","first-page":"S23","volume":"12","year":"2007","unstructured":"Dierynk, I., S. De Meyer, K. Cao-Van, S. Van Marck, E. Lathouwers, K. Thys, B. Maes, and M. P. de B\u00e9thune. 2007. Impact of gag cleavage site mutation on the virological response to darunavir\/ritonavir in treatment-experienced patients in POWER 1, 2 and 3. Antivir. Ther.12:S23.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.6.3763-3769.1996"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1994.10.1359"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20770"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1994.10.343"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.269"},{"key":"e_1_3_2_19_2","unstructured":"Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor 2007"},{"key":"e_1_3_2_20_2","unstructured":"HIV sequence compendium 2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2144-2146.2001"},{"key":"e_1_3_2_22_2","unstructured":"Changes in the V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the Motivate 1 and 2 trials 2008"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4628-4637.2004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/589289"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.15.7398-7406.2002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200206140-00004"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.08.033"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040152"},{"key":"e_1_3_2_30_2","first-page":"661","volume":"13","year":"1999","unstructured":"Palmer, S., R. W. Shafer, and T. C. Merigan. 1999. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS13:661-667.","journal-title":"AIDS"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00009"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.437-443.2004"},{"key":"e_1_3_2_33_2","first-page":"S116","volume":"10","year":"2005","unstructured":"Parkin, N., C. Chappey, E. Lam, and C. Petropoulos. 2005. Reduced susceptibility to protease inhibitors (PI) in the absence of primary resistance-associated mutations. Antivir. Ther.10:S116.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/343470a0"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.920-928.2000"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-1-2"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.1.31-35.2002"},{"key":"e_1_3_2_38_2","first-page":"493","volume":"27","year":"1938","unstructured":"Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg.27:493-497.","journal-title":"Am. J. Hyg."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.252469399"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.8.4991-4999.2005"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/135965350300800212","volume":"8","year":"2003","unstructured":"R\u00f8ge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft. 2003. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther.8:173-182.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001781"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.04.001"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.694-701.2006"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1484"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.7.3210-3222.2004"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","volume":"7","year":"2002","unstructured":"Van Laethem, K., A. De Luca, A. Antinori, A. Cingolani, C. F. Perno, and A. M. Vandamme. 2002. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. Antivir. Ther.7:123-129.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.09.003"},{"key":"e_1_3_2_49_2","first-page":"37","volume":"8","year":"2006","unstructured":"Van Laethem, K., and A. M. Vandamme. 2006. Interpreting resistance data for HIV-1 therapy management\u2014know the limitations. AIDS Rev.8:37-43.","journal-title":"AIDS Rev."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.10.008"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.07.008"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2005.00011.x"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/135965350400900501","volume":"9","year":"2004","unstructured":"Wang, K., R. Samudrala, and J. E. Mittler. 2004. Antivirogram or phenosense: a comparison of their reproducibility and an analysis of their correlation. Antivir. Ther.9:703-712.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2006.04.004"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02006-06"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3478-3484.2003"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040335"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01739-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01739-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T23:42:43Z","timestamp":1684971763000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01739-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1128\/JCM.01739-08"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01739-08","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"2008-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}